FIGURE 3 Response to gefitinib in extensive leptomeningeal carcinomatosis
From the following article:
Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation
Nicholas W Choong, Sascha Dietrich, Tanguy Y Seiwert, Maria S Tretiakova, Vidya Nallasura, Gareth C Davies, Stanley Lipkowitz, Aliya N Husain, Ravi Salgia and Patrick C Ma
BACK TO ARTICLE
Figure 3. Response to gefitinib in extensive leptomeningeal carcinomatosis
MRI scan of the lower thoracic and lumbar spine (A,B) prior to starting gefitinib, and (C,D) 2 months after gefitinib monotherapy, demonstrating a dramatic reduction in the number and enhancement of leptomeningeal metastases (solid white arrows), correlating with the positive clinical response.
